# Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin Lymphoma

> **NCT04788043** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Stanford University** · enrollment: 8 (actual)

## Conditions studied

- Hodgkin Lymphoma
- Classic Hodgkin Lymphoma
- Relapsed Classical Hodgkin Lymphoma
- Refractory Classic Hodgkin Lymphoma

## Interventions

- **DRUG:** Magrolimab
- **DRUG:** Pembrolizumab
- **PROCEDURE:** PET/CT

## Key facts

- **NCT ID:** NCT04788043
- **Lead sponsor:** Stanford University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-06-21
- **Primary completion:** 2026-10
- **Final completion:** 2027-10
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2025-04-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04788043

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04788043, "Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin Lymphoma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04788043. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*